Cost-effectiveness of national health insurance programs in high-income countries: A systematic review

Abstract

ObjectivesNational health insurance is now common in most developed countries. This study reviews the evidence and synthesizes the cost-effectiveness information for national health insurance or disability insurance programs across high-income countries.Data sourcesA literature search using health, economics and systematic review electronic databases (PubMed, Embase, Medline, Econlit, RepEc, Cochrane library and Campbell library), was conducted from April to October 2015.Study selectionTwo reviewers independently selected relevant studies by applying screening criteria to the title and keywords fields, followed by a detailed examination of abstracts.Data extractionStudies were selected for data extraction using a quality assessment form consisting of five questions. Only studies with positive answers to all five screening questions were selected for data extraction. Data were entered into a data extraction form by one reviewer and verified by another.Evidence synthesisData on costs and quality of life in control and treatment groups were used to draw distributions for synthesis. We chose the log-normal distribution for both cost and quality-of-life data to reflect non-negative value and high skew. The results were synthesized using a Monte Carlo simulation, with 10,000 repetitions, to estimate the overall cost-effectiveness of national health insurance programs.ResultsFour studies from the United States that examined the cost-effectiveness of national health insurance were included in the review. One study examined the effects of medical expenditure, and the remaining studies examined the cost-effectiveness of health insurance reforms. The incremental cost-effectiveness ratio (ICER) ranged from US$23,000 to US$64,000 per QALY. The combined results showed that national health insurance is associated with an average incremental cost-effectiveness ratio of US$51,300 per quality-adjusted life year (QALY). Based on the standard threshold for cost-effectiveness, national insurance programs are cost-effective interventions.ConclusionsAlthough national health insurance programs have been introduced in most developed countries, only a few studies have examined their cost-effectiveness. All the selected studies revealed strong evidence to support health insurance programs or health reforms in the United States. The average ICER in this study is below the standard threshold for cost-effectiveness used in the US. The small number of relevant studies is the main limitation of this study.

Are Lockdowns Effective in Managing Pandemics?

“…Cost-effectiveness analysis is routinely performed in health policy. It is widely assumed (though far not unanimously) that the state should not provide citizens with services (including life-extension services) that are less cost-effective than the citizens themselves are willing to pay for such services [ 37 ]. Very different values for the cost-effectiveness threshold (CET) can be found in the literature.…”

Cost-Effectiveness Threshold for Healthcare: Justification and Quantification

“…It has been estimated that the U.S. national health insurance is associated with an average cost-effectiveness of about US$ 50,000 per QALY (quality-adjusted life year) gained. 13 It is true that values used for decision-making often have an upper limit in the $100,000 to $150,000/QALY or higher, as mentioned by Birch and Gafni 32 or Padula et al 33 However, Padula et al 33 note that there is a strong association between estimated ICER (incremental cost-effectiveness ratio) values and chosen CET: the regression analysis indicated that CETs have a baseline value of $52,000 and grow by $0.37 for each dollar increase in the estimated ICER. Therefore, higher CET values seem to be biased.…”

Cost-Effectiveness of Pharmacogenomics-Guided Prescribing to Prevent Gene-Drug-Related Deaths: A Decision-Analytic Model

“…The weighted average certainty score for this analysis 2.5 (fairly certain). In high-income countries an intervention is considered cost-effective when one gained quality-adjusted life year (QALY) costs less than a threshold between €20,000–60,000 ( Nghiem et al, 2017 ). Since PGx-guided pharmacotherapy prevents gene-drug related deaths, it will contribute numerous QALYs; the magnitude of which is associated with the number of additional years that is gained by preventing the fatal gene-drug associated ADR.…”